Secondary Logo

Journal Logo

Oncology drugs

Dalal, Kavitha S. PharmD; Bridgeman, Mary Barna PharmD, BCPS, BCGP

doi: 10.1097/01.NURSE.0000585932.20664.b8
Department: DRUG CHALLENGE
Free

Can you identify these oncology drugs?

Kavitha S. Dalal is a critical care pharmacist at Virtua in Marlton, N.J. Mary Barna Bridgeman is a clinical associate professor at Rutgers University Ernest Mario School of Pharmacy in Piscataway, N.J.

Unless otherwise specified, the information in the preceding summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breastfeeding. Also consult a pharmacist, the package insert, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions.

CAN YOU IDENTIFY these oncology medications? To find out, match each brand name in Section I with its generic name and description in Section II.

Back to Top | Article Outline

Section I

______ 1. Poteligeo (Kyowa Kirin)

______ 2. Erleada (Janssen)

______ 3. Mektovi (Array BioPharma)

Back to Top | Article Outline

Section II

a. mogamulizumab-kpkc. Designated as a CC chemokine receptor type 4-directed monoclonal antibody, this drug is indicated to treat adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. It is administered I.V. over at least 60 minutes on days 1, 8, 15, and 22 of the first 28-day cycle and on days 1 and 15 of each subsequent cycle. Because life-threatening infusion reactions and dermatologic toxicity are possible, premedication with diphenhydramine and acetaminophen for the first infusion is recommended.

b. apalutamide. Administered orally, this androgen receptor inhibitor is used to treat nonmetastatic, castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Patients who have not had bilateral orchiectomy should receive a gonadotropin-releasing hormone analogue concurrently. In clinical trials, some patients experienced fractures and falls, so assess patients for fall risk.

c. binimetinib. This oral kinase inhibitor is indicated in combination with encorafenib to treat unresectable or metastatic melanoma with a BRAF V600E or V600K mutation confirmed with an FDA-approved test. The most common adverse reactions include fatigue, nausea, vomiting, and abdominal pain. Educate patients about possible serious adverse reactions such as cardiomyopathy, venous thromboembolism, interstitial lung disease, hemorrhage, and ocular toxicities.

Answers: 1a, 2b, 3c

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.